TABLE 7.
The details of trials with available results.
| NCT number | Drug name | Phase | Specific conditions | Primary end point | IF/CN |
|---|---|---|---|---|---|
| NCT04073784 | Toripalimab | Phase 1 | Locoregionally Advanced | N/A | 17.0 |
| NCT02605967 | Spartalizumab | Phase 2 | R/M | Negative | 11.5 |
| NCT03097939 | Nivolumab and Ipilimumab | Phase 2 | R/M | Negative | 16.6 |
| NCT02339558 | Nivolumab | Phase 2 | R/M | N/A | 45.3 |
| NCT03924986 | Tislelizumab | Phase 3 | R/M | Positive | 50.3 |
| NCT03854838 | Toripalimab | Phase 2 | R | N/A | 10.9 |
| NCT02915432 | Toripalimab | Phase 1|Phase 2 | R/M | N/A | 45.3 |
| NCT03581786 | Toripalimab | Phase 3 | R/M | Positive | 82.9 |
| NCT02538510 | Pembrolizumab | Phase 1|Phase 2 | R/M | N/A | 11.5 |
| NCT03074513 | Atezolizumab | Phase 2 | Stage IV AJCC v7 | N/A | 28.4 |
| NCT03707509 | Camrelizumab | Phase 3 | R/M | Positive | 51.1 |
| NCT03121716 | Camrelizumab | Phase 1 | R/M | N/A | 51.1 |
| NCT05448885 | Tislelizumab | Phase 2 | Locoregionally Advanced | N/A | ESMO |
| NCT05166577 | Pembrolizumab | Phase 1|Phase 2 | R/M | N/A | ESMO |
| NCT05549466 | Camrelizumab | Phase 2 | R/M | N/A | ASCO |
| NCT03866967 | Penpulimab | Phase 2 | M | Positive | ESMO |
| NCT03558191 | Camrelizumab | Phase 2 | R/M | Positive | ESMO |
Abbreviation: R/M, Recurrent/metastatic nasopharyngeal carcinoma; N/A, not applicable; IF, impact factor; CN, conference name; AJCC, the american joint committee on cancer.